Search clinical trials for: Ceplene®, IL-2, Azacitidine

Total 1433 results

Groupe Francophone des Myelodysplasies
EpiCept Corporation

Withdrawn

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Vastra Gotaland Region
Karolinska University Hospital; Sahlgrenska University Hospital, Sweden; Nordic...

Unknown

A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)

Leukemia, Myelomonocytic, Chronic

Sweden
Cytovia, Inc.
EpiCept Corporation

Completed

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

Acute Myeloid Leukemia

Sweden
Fred Hutchinson Cancer Center

Completed

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Benjamin Tomlinson

Recruiting

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Myelodysplastic Syndromes | MDS/MPN Crossover Syndromes

United States
Shirley Ryan AbilityLab
Rady Children's Hospital, San Diego

Not yet recruiting

Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy

Cerebral Palsy | Contracture
Peking University Third Hospital

Recruiting

Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Amyotrophic Lateral Sclerosis

China
Brigham and Women's Hospital

Terminated

Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA

Abdominal Wall Defect | Amputation, Traumatic | Amputation;Traumatic;Old | Face Injury | Face; Deformity

United States
Peking University People's Hospital

Unknown

The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients

Infection

China
jiangjingting

Unknown

Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

Lymphoma, B Cell

China
University of Chicago

Terminated

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
The University of Texas Health Science Center,...

Recruiting

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma (5-AZA)

Recurrent Ependymoma

United States
National Cancer Institute (NCI)

Completed

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

Melanoma | Neoplasm Metastasis

United States
Celgene

Active, not recruiting

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (QUAZAR AML-001)

Leukemia, Myeloid, Acute

United States, Australia, Brazil, Canada, Czechia, Finland, France, Germany, Italy, Korea, Republic of, Mexico, Portugal, Russian Federation, Spain, United Kingdom, Belgium, Taiwan, Austria, Ireland, Israel, Lithuania, Poland, Turkey
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Recurrent Myeloproliferative Neoplasm

United States
National Cancer Institute (NCI)

Completed

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
University of Minnesota

Completed

Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2

HIV

United States
Celyad Oncology SA

Withdrawn

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (EPITHINK)

Myelodysplastic Syndromes | AML, Adult
National Cancer Institute (NCI)

Terminated

Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

Sarcoma | Breast Neoplasm | Lung Neoplasm | Kidney Neoplasm

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers (HEALTHIL-2)

Healthy Volunteers

France
Hackensack Meridian Health

Terminated

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus (T-REG)

Graft Versus Host Disease

United States
Stanford University
Celgene Corporation

Terminated

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Leukemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Hematologic and Lymphocytic Disorder | Acute Myeloid Leukemia in Remission | FLT3 Gene Mutation | Minimal Residual Disease Persistence

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Oxford BioMedica
The Methodist Hospital Research Institute; ORION Clinical Services

Completed

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
Iltoo Pharma

Completed

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) (LUPIL-2)

Systemic Lupus Erythematosus

France, Spain, Mexico, Austria, Germany, Bulgaria, Italy, Mauritius, Portugal, Romania
Vical

Completed

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Rhabdomyosarcoma | Ewing's Sarcoma

United States
Belarusian Research Center for Pediatric Oncology...

Completed

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Leukemia, Acute Lymphoblastic | Leukemia, Acute Myeloid

Belarus
BioNTech US Inc.

Recruiting

NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

Belgium, Netherlands, Spain
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia

United States
OncBioMune Pharmaceuticals
United States Department of Defense

Unknown

Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PSA)

Prostate Cancer

United States
Istituto Giannina Gaslini

Completed

IL-2 for Multi Drug Resistant Nephrotic Syndrome

Nephrotic Syndrome

Italy
Beijing 302 Hospital

Not yet recruiting

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Minimal Residual Disease | Relapsed Acute Myeloid Leukemia
Novartis Pharmaceuticals

Completed

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Myelodysplastic Syndromes | Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Preleukemia | Chronic Myelomonocytic Leukemia

United States, France, Australia, Netherlands, Spain, Germany, United Kingdom, Finland
Jeffrey Bluestone
Yale University

Completed

T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)

Type 1 Diabetes Mellitus

United States
Peking University People's Hospital
Monash University; Beijing ShuangLu Pharmaceutical Co., Ltd.

Unknown

A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Uma Borate

Recruiting

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Neutrophilic Leukemia | Myeloid Neoplasm | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative... and other conditions

United States
Brian Jonas
National Cancer Institute (NCI); AbbVie

Recruiting

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia

United States
Henry Ford Health System

Recruiting

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Myeloid Malignancy

United States
Fuzhou General Hospital

Unknown

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

China
Celgene
AbbVie

Completed

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (OMNIVERSE)

Leukemia, Myeloid, Acute

United States, Australia
GT Biopharma, Inc.

Terminated

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Acute Myelogenous Leukemia | Systemic Mastocytosis | Mast Cell Leukemia | High-risk Myelodysplastic Syndromes

United States
Nanexa AB
Uppsala University

Completed

Pharmacokinetics, Tolerability and Safety of NEX-18a

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Sweden
AgonOx, Inc.
Providence St Joseph Health; Phio Pharmaceuticals Corp.

Recruiting

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (ACT)

Melanoma | Gynecologic Cancer | Colorectal Cancer | Lung Cancer | HNSCC | Urogenital Cancer

United States
University Hospital, Limoges

Withdrawn

Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study (NIL-2 pilote)

Nephrotic Syndrome Steroid-Dependent | Interleukin 2

Search clinical trials for: Ceplene®, IL-2, Azacitidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations